Global Fiducial Markers Market

Fiducial Markers Comprehensive Study by Type (Polymer-Based Markers, Metal-Based Markers, Others), Application (Hospitals, Radiotherapy Centers, Cancer Research Institutes, Others), Cancer (Prostate Cancer, Lung Cancer, Breast Cancer, Gastric Cancer, Other Cancers), Modality (CT/CBCT, MRI, Ultrasound, Radiotherapy) Players and Region - Global Market Outlook to 2030

Fiducial Markers Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Fiducial Markers
Fiducial markers are tiny metal objects of about the size of a grain of rice. They allow doctors to line up the beams of radiation to make sure that the radiation therapy of patient is delivered exactly the same way each time. This helps them to target tumor and avoid healthy tissue. The fiducial markers will stay in prostate after your treatment.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Fiducial Markers market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

CIVCO Radiotherapy (United States), IZI Medical Products (United States), Boston Scientific Corporation (United States), Naslund Medical AB (Sweden), IBA (Belgium), Best Medical International, Inc. (United States), Nanovi A/S (Denmark), Carbon Medical Technologies (United States), Eckert & Ziegler (Germany) and Innovative Oncology Solutions (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Medtronic (Ireland), QlRad Inc. (United States), JJ-Medtech (Netherlands) and QFIX (United States).

Segmentation Overview
AMA Research has segmented the market of Global Fiducial Markers market by Type (Polymer-Based Markers, Metal-Based Markers and Others), Application (Hospitals, Radiotherapy Centers, Cancer Research Institutes and Others) and Region.



On the basis of geography, the market of Fiducial Markers has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Cancer , the sub-segment i.e. Prostate Cancer will boost the Fiducial Markers market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Modality, the sub-segment i.e. CT/CBCT will boost the Fiducial Markers market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Investments and Funding for Cancer Research

Market Growth Drivers:
Growing Incidence of Cancer, Improving Reimbursement Scenario and Rising Awareness on Radiotherapy

Challenges:
Complications Associated With the Placement of Fiducial Markers and Shortage of Trained Personnel

Restraints:
Lack of Adequate Healthcare Infrastructure and Premium Pricing of Modalities and Alternative Therapies and High Marker Costs

Opportunities:
Increasing use in emerging regions

Market Leaders and their expansionary development strategies
In December 2019, IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of solutions for the diagnosis and treatment of cancer, announces that it has sold RadioMed Corporation (“RadioMed”), IBA’s VISICOIL fiducial markers business, to IZI Medical Products LLC, a leading interventional medical device company in a deal that is worth between USD 14 and 16 million to IBA.
In May 2022, CIVCO Radiotherapy, the leading global provider of high quality, innovative, patient-centric radiotherapy solutions, announced the release of the Universal Couchtop ProForm Head & Neck Solution, the newest development in their ProtonSeries family of products for proton therapy.


Key Target Audience
Fiducial Markers Manufacturer, Investor, Research and Development, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Polymer-Based Markers
  • Metal-Based Markers
  • Others
By Application
  • Hospitals
  • Radiotherapy Centers
  • Cancer Research Institutes
  • Others
By Cancer
  • Prostate Cancer
  • Lung Cancer
  • Breast Cancer
  • Gastric Cancer
  • Other Cancers

By Modality
  • CT/CBCT
  • MRI
  • Ultrasound
  • Radiotherapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Incidence of Cancer
      • 3.2.2. Improving Reimbursement Scenario
      • 3.2.3. Rising Awareness on Radiotherapy
    • 3.3. Market Challenges
      • 3.3.1. Complications Associated With the Placement of Fiducial Markers
      • 3.3.2. Shortage of Trained Personnel
    • 3.4. Market Trends
      • 3.4.1. Rising Investments and Funding for Cancer Research
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Fiducial Markers, by Type, Application, Cancer , Modality and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Fiducial Markers (Value)
      • 5.2.1. Global Fiducial Markers by: Type (Value)
        • 5.2.1.1. Polymer-Based Markers
        • 5.2.1.2. Metal-Based Markers
        • 5.2.1.3. Others
      • 5.2.2. Global Fiducial Markers by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Radiotherapy Centers
        • 5.2.2.3. Cancer Research Institutes
        • 5.2.2.4. Others
      • 5.2.3. Global Fiducial Markers by: Modality (Value)
        • 5.2.3.1. CT/CBCT
        • 5.2.3.2. MRI
        • 5.2.3.3. Ultrasound
        • 5.2.3.4. Radiotherapy
      • 5.2.4. Global Fiducial Markers Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Fiducial Markers (Volume)
      • 5.3.1. Global Fiducial Markers by: Type (Volume)
        • 5.3.1.1. Polymer-Based Markers
        • 5.3.1.2. Metal-Based Markers
        • 5.3.1.3. Others
      • 5.3.2. Global Fiducial Markers by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Radiotherapy Centers
        • 5.3.2.3. Cancer Research Institutes
        • 5.3.2.4. Others
      • 5.3.3. Global Fiducial Markers by: Modality (Volume)
        • 5.3.3.1. CT/CBCT
        • 5.3.3.2. MRI
        • 5.3.3.3. Ultrasound
        • 5.3.3.4. Radiotherapy
      • 5.3.4. Global Fiducial Markers Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Fiducial Markers (Price)
      • 5.4.1. Global Fiducial Markers by: Type (Price)
  • 6. Fiducial Markers: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CIVCO Radiotherapy (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. IZI Medical Products (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boston Scientific Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Naslund Medical AB (Sweden)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. IBA (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Best Medical International, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nanovi A/S (Denmark)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Carbon Medical Technologies (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eckert & Ziegler (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Innovative Oncology Solutions (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Fiducial Markers Sale, by Type, Application, Cancer , Modality and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Fiducial Markers (Value)
      • 7.2.1. Global Fiducial Markers by: Type (Value)
        • 7.2.1.1. Polymer-Based Markers
        • 7.2.1.2. Metal-Based Markers
        • 7.2.1.3. Others
      • 7.2.2. Global Fiducial Markers by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Radiotherapy Centers
        • 7.2.2.3. Cancer Research Institutes
        • 7.2.2.4. Others
      • 7.2.3. Global Fiducial Markers by: Modality (Value)
        • 7.2.3.1. CT/CBCT
        • 7.2.3.2. MRI
        • 7.2.3.3. Ultrasound
        • 7.2.3.4. Radiotherapy
      • 7.2.4. Global Fiducial Markers Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Fiducial Markers (Volume)
      • 7.3.1. Global Fiducial Markers by: Type (Volume)
        • 7.3.1.1. Polymer-Based Markers
        • 7.3.1.2. Metal-Based Markers
        • 7.3.1.3. Others
      • 7.3.2. Global Fiducial Markers by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Radiotherapy Centers
        • 7.3.2.3. Cancer Research Institutes
        • 7.3.2.4. Others
      • 7.3.3. Global Fiducial Markers by: Modality (Volume)
        • 7.3.3.1. CT/CBCT
        • 7.3.3.2. MRI
        • 7.3.3.3. Ultrasound
        • 7.3.3.4. Radiotherapy
      • 7.3.4. Global Fiducial Markers Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Fiducial Markers (Price)
      • 7.4.1. Global Fiducial Markers by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Fiducial Markers: by Type(USD Million)
  • Table 2. Fiducial Markers Polymer-Based Markers , by Region USD Million (2018-2023)
  • Table 3. Fiducial Markers Metal-Based Markers , by Region USD Million (2018-2023)
  • Table 4. Fiducial Markers Others , by Region USD Million (2018-2023)
  • Table 5. Fiducial Markers: by Application(USD Million)
  • Table 6. Fiducial Markers Hospitals , by Region USD Million (2018-2023)
  • Table 7. Fiducial Markers Radiotherapy Centers , by Region USD Million (2018-2023)
  • Table 8. Fiducial Markers Cancer Research Institutes , by Region USD Million (2018-2023)
  • Table 9. Fiducial Markers Others , by Region USD Million (2018-2023)
  • Table 10. Fiducial Markers: by Modality(USD Million)
  • Table 11. Fiducial Markers CT/CBCT , by Region USD Million (2018-2023)
  • Table 12. Fiducial Markers MRI , by Region USD Million (2018-2023)
  • Table 13. Fiducial Markers Ultrasound , by Region USD Million (2018-2023)
  • Table 14. Fiducial Markers Radiotherapy , by Region USD Million (2018-2023)
  • Table 15. South America Fiducial Markers, by Country USD Million (2018-2023)
  • Table 16. South America Fiducial Markers, by Type USD Million (2018-2023)
  • Table 17. South America Fiducial Markers, by Application USD Million (2018-2023)
  • Table 18. South America Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 19. South America Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 20. Brazil Fiducial Markers, by Type USD Million (2018-2023)
  • Table 21. Brazil Fiducial Markers, by Application USD Million (2018-2023)
  • Table 22. Brazil Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 23. Brazil Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 24. Argentina Fiducial Markers, by Type USD Million (2018-2023)
  • Table 25. Argentina Fiducial Markers, by Application USD Million (2018-2023)
  • Table 26. Argentina Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 27. Argentina Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 28. Rest of South America Fiducial Markers, by Type USD Million (2018-2023)
  • Table 29. Rest of South America Fiducial Markers, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 31. Rest of South America Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 32. Asia Pacific Fiducial Markers, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Fiducial Markers, by Type USD Million (2018-2023)
  • Table 34. Asia Pacific Fiducial Markers, by Application USD Million (2018-2023)
  • Table 35. Asia Pacific Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 36. Asia Pacific Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 37. China Fiducial Markers, by Type USD Million (2018-2023)
  • Table 38. China Fiducial Markers, by Application USD Million (2018-2023)
  • Table 39. China Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 40. China Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 41. Japan Fiducial Markers, by Type USD Million (2018-2023)
  • Table 42. Japan Fiducial Markers, by Application USD Million (2018-2023)
  • Table 43. Japan Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 44. Japan Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 45. India Fiducial Markers, by Type USD Million (2018-2023)
  • Table 46. India Fiducial Markers, by Application USD Million (2018-2023)
  • Table 47. India Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 48. India Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 49. South Korea Fiducial Markers, by Type USD Million (2018-2023)
  • Table 50. South Korea Fiducial Markers, by Application USD Million (2018-2023)
  • Table 51. South Korea Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 52. South Korea Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 53. Taiwan Fiducial Markers, by Type USD Million (2018-2023)
  • Table 54. Taiwan Fiducial Markers, by Application USD Million (2018-2023)
  • Table 55. Taiwan Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 56. Taiwan Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 57. Australia Fiducial Markers, by Type USD Million (2018-2023)
  • Table 58. Australia Fiducial Markers, by Application USD Million (2018-2023)
  • Table 59. Australia Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 60. Australia Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Fiducial Markers, by Type USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Fiducial Markers, by Application USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 65. Europe Fiducial Markers, by Country USD Million (2018-2023)
  • Table 66. Europe Fiducial Markers, by Type USD Million (2018-2023)
  • Table 67. Europe Fiducial Markers, by Application USD Million (2018-2023)
  • Table 68. Europe Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 69. Europe Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 70. Germany Fiducial Markers, by Type USD Million (2018-2023)
  • Table 71. Germany Fiducial Markers, by Application USD Million (2018-2023)
  • Table 72. Germany Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 73. Germany Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 74. France Fiducial Markers, by Type USD Million (2018-2023)
  • Table 75. France Fiducial Markers, by Application USD Million (2018-2023)
  • Table 76. France Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 77. France Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 78. Italy Fiducial Markers, by Type USD Million (2018-2023)
  • Table 79. Italy Fiducial Markers, by Application USD Million (2018-2023)
  • Table 80. Italy Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 81. Italy Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 82. United Kingdom Fiducial Markers, by Type USD Million (2018-2023)
  • Table 83. United Kingdom Fiducial Markers, by Application USD Million (2018-2023)
  • Table 84. United Kingdom Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 85. United Kingdom Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 86. Netherlands Fiducial Markers, by Type USD Million (2018-2023)
  • Table 87. Netherlands Fiducial Markers, by Application USD Million (2018-2023)
  • Table 88. Netherlands Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 89. Netherlands Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 90. Rest of Europe Fiducial Markers, by Type USD Million (2018-2023)
  • Table 91. Rest of Europe Fiducial Markers, by Application USD Million (2018-2023)
  • Table 92. Rest of Europe Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 93. Rest of Europe Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 94. MEA Fiducial Markers, by Country USD Million (2018-2023)
  • Table 95. MEA Fiducial Markers, by Type USD Million (2018-2023)
  • Table 96. MEA Fiducial Markers, by Application USD Million (2018-2023)
  • Table 97. MEA Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 98. MEA Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 99. Middle East Fiducial Markers, by Type USD Million (2018-2023)
  • Table 100. Middle East Fiducial Markers, by Application USD Million (2018-2023)
  • Table 101. Middle East Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 102. Middle East Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 103. Africa Fiducial Markers, by Type USD Million (2018-2023)
  • Table 104. Africa Fiducial Markers, by Application USD Million (2018-2023)
  • Table 105. Africa Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 106. Africa Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 107. North America Fiducial Markers, by Country USD Million (2018-2023)
  • Table 108. North America Fiducial Markers, by Type USD Million (2018-2023)
  • Table 109. North America Fiducial Markers, by Application USD Million (2018-2023)
  • Table 110. North America Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 111. North America Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 112. United States Fiducial Markers, by Type USD Million (2018-2023)
  • Table 113. United States Fiducial Markers, by Application USD Million (2018-2023)
  • Table 114. United States Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 115. United States Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 116. Canada Fiducial Markers, by Type USD Million (2018-2023)
  • Table 117. Canada Fiducial Markers, by Application USD Million (2018-2023)
  • Table 118. Canada Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 119. Canada Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 120. Mexico Fiducial Markers, by Type USD Million (2018-2023)
  • Table 121. Mexico Fiducial Markers, by Application USD Million (2018-2023)
  • Table 122. Mexico Fiducial Markers, by Cancer USD Million (2018-2023)
  • Table 123. Mexico Fiducial Markers, by Modality USD Million (2018-2023)
  • Table 124. Fiducial Markers Sales: by Type(K Unit)
  • Table 125. Fiducial Markers Sales Polymer-Based Markers , by Region K Unit (2018-2023)
  • Table 126. Fiducial Markers Sales Metal-Based Markers , by Region K Unit (2018-2023)
  • Table 127. Fiducial Markers Sales Others , by Region K Unit (2018-2023)
  • Table 128. Fiducial Markers Sales: by Application(K Unit)
  • Table 129. Fiducial Markers Sales Hospitals , by Region K Unit (2018-2023)
  • Table 130. Fiducial Markers Sales Radiotherapy Centers , by Region K Unit (2018-2023)
  • Table 131. Fiducial Markers Sales Cancer Research Institutes , by Region K Unit (2018-2023)
  • Table 132. Fiducial Markers Sales Others , by Region K Unit (2018-2023)
  • Table 133. Fiducial Markers Sales: by Modality(K Unit)
  • Table 134. Fiducial Markers Sales CT/CBCT , by Region K Unit (2018-2023)
  • Table 135. Fiducial Markers Sales MRI , by Region K Unit (2018-2023)
  • Table 136. Fiducial Markers Sales Ultrasound , by Region K Unit (2018-2023)
  • Table 137. Fiducial Markers Sales Radiotherapy , by Region K Unit (2018-2023)
  • Table 138. South America Fiducial Markers Sales, by Country K Unit (2018-2023)
  • Table 139. South America Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 140. South America Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 141. South America Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 142. South America Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 143. Brazil Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 144. Brazil Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 145. Brazil Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 146. Brazil Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 147. Argentina Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 148. Argentina Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 149. Argentina Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 150. Argentina Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 151. Rest of South America Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 152. Rest of South America Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 153. Rest of South America Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 154. Rest of South America Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 155. Asia Pacific Fiducial Markers Sales, by Country K Unit (2018-2023)
  • Table 156. Asia Pacific Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 157. Asia Pacific Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 158. Asia Pacific Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 159. Asia Pacific Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 160. China Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 161. China Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 162. China Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 163. China Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 164. Japan Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 165. Japan Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 166. Japan Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 167. Japan Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 168. India Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 169. India Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 170. India Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 171. India Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 172. South Korea Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 173. South Korea Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 174. South Korea Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 175. South Korea Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 176. Taiwan Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 177. Taiwan Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 178. Taiwan Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 179. Taiwan Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 180. Australia Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 181. Australia Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 182. Australia Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 183. Australia Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 184. Rest of Asia-Pacific Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 185. Rest of Asia-Pacific Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 186. Rest of Asia-Pacific Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 187. Rest of Asia-Pacific Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 188. Europe Fiducial Markers Sales, by Country K Unit (2018-2023)
  • Table 189. Europe Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 190. Europe Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 191. Europe Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 192. Europe Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 193. Germany Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 194. Germany Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 195. Germany Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 196. Germany Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 197. France Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 198. France Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 199. France Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 200. France Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 201. Italy Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 202. Italy Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 203. Italy Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 204. Italy Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 205. United Kingdom Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 206. United Kingdom Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 207. United Kingdom Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 208. United Kingdom Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 209. Netherlands Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 210. Netherlands Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 211. Netherlands Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 212. Netherlands Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 213. Rest of Europe Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 214. Rest of Europe Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 215. Rest of Europe Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 216. Rest of Europe Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 217. MEA Fiducial Markers Sales, by Country K Unit (2018-2023)
  • Table 218. MEA Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 219. MEA Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 220. MEA Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 221. MEA Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 222. Middle East Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 223. Middle East Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 224. Middle East Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 225. Middle East Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 226. Africa Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 227. Africa Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 228. Africa Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 229. Africa Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 230. North America Fiducial Markers Sales, by Country K Unit (2018-2023)
  • Table 231. North America Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 232. North America Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 233. North America Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 234. North America Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 235. United States Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 236. United States Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 237. United States Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 238. United States Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 239. Canada Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 240. Canada Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 241. Canada Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 242. Canada Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 243. Mexico Fiducial Markers Sales, by Type K Unit (2018-2023)
  • Table 244. Mexico Fiducial Markers Sales, by Application K Unit (2018-2023)
  • Table 245. Mexico Fiducial Markers Sales, by Cancer K Unit (2018-2023)
  • Table 246. Mexico Fiducial Markers Sales, by Modality K Unit (2018-2023)
  • Table 247. Fiducial Markers: by Type(USD/Units)
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Fiducial Markers: by Type(USD Million)
  • Table 259. Fiducial Markers Polymer-Based Markers , by Region USD Million (2025-2030)
  • Table 260. Fiducial Markers Metal-Based Markers , by Region USD Million (2025-2030)
  • Table 261. Fiducial Markers Others , by Region USD Million (2025-2030)
  • Table 262. Fiducial Markers: by Application(USD Million)
  • Table 263. Fiducial Markers Hospitals , by Region USD Million (2025-2030)
  • Table 264. Fiducial Markers Radiotherapy Centers , by Region USD Million (2025-2030)
  • Table 265. Fiducial Markers Cancer Research Institutes , by Region USD Million (2025-2030)
  • Table 266. Fiducial Markers Others , by Region USD Million (2025-2030)
  • Table 267. Fiducial Markers: by Modality(USD Million)
  • Table 268. Fiducial Markers CT/CBCT , by Region USD Million (2025-2030)
  • Table 269. Fiducial Markers MRI , by Region USD Million (2025-2030)
  • Table 270. Fiducial Markers Ultrasound , by Region USD Million (2025-2030)
  • Table 271. Fiducial Markers Radiotherapy , by Region USD Million (2025-2030)
  • Table 272. South America Fiducial Markers, by Country USD Million (2025-2030)
  • Table 273. South America Fiducial Markers, by Type USD Million (2025-2030)
  • Table 274. South America Fiducial Markers, by Application USD Million (2025-2030)
  • Table 275. South America Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 276. South America Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 277. Brazil Fiducial Markers, by Type USD Million (2025-2030)
  • Table 278. Brazil Fiducial Markers, by Application USD Million (2025-2030)
  • Table 279. Brazil Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 280. Brazil Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 281. Argentina Fiducial Markers, by Type USD Million (2025-2030)
  • Table 282. Argentina Fiducial Markers, by Application USD Million (2025-2030)
  • Table 283. Argentina Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 284. Argentina Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 285. Rest of South America Fiducial Markers, by Type USD Million (2025-2030)
  • Table 286. Rest of South America Fiducial Markers, by Application USD Million (2025-2030)
  • Table 287. Rest of South America Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 288. Rest of South America Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 289. Asia Pacific Fiducial Markers, by Country USD Million (2025-2030)
  • Table 290. Asia Pacific Fiducial Markers, by Type USD Million (2025-2030)
  • Table 291. Asia Pacific Fiducial Markers, by Application USD Million (2025-2030)
  • Table 292. Asia Pacific Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 293. Asia Pacific Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 294. China Fiducial Markers, by Type USD Million (2025-2030)
  • Table 295. China Fiducial Markers, by Application USD Million (2025-2030)
  • Table 296. China Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 297. China Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 298. Japan Fiducial Markers, by Type USD Million (2025-2030)
  • Table 299. Japan Fiducial Markers, by Application USD Million (2025-2030)
  • Table 300. Japan Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 301. Japan Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 302. India Fiducial Markers, by Type USD Million (2025-2030)
  • Table 303. India Fiducial Markers, by Application USD Million (2025-2030)
  • Table 304. India Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 305. India Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 306. South Korea Fiducial Markers, by Type USD Million (2025-2030)
  • Table 307. South Korea Fiducial Markers, by Application USD Million (2025-2030)
  • Table 308. South Korea Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 309. South Korea Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 310. Taiwan Fiducial Markers, by Type USD Million (2025-2030)
  • Table 311. Taiwan Fiducial Markers, by Application USD Million (2025-2030)
  • Table 312. Taiwan Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 313. Taiwan Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 314. Australia Fiducial Markers, by Type USD Million (2025-2030)
  • Table 315. Australia Fiducial Markers, by Application USD Million (2025-2030)
  • Table 316. Australia Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 317. Australia Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 318. Rest of Asia-Pacific Fiducial Markers, by Type USD Million (2025-2030)
  • Table 319. Rest of Asia-Pacific Fiducial Markers, by Application USD Million (2025-2030)
  • Table 320. Rest of Asia-Pacific Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 321. Rest of Asia-Pacific Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 322. Europe Fiducial Markers, by Country USD Million (2025-2030)
  • Table 323. Europe Fiducial Markers, by Type USD Million (2025-2030)
  • Table 324. Europe Fiducial Markers, by Application USD Million (2025-2030)
  • Table 325. Europe Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 326. Europe Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 327. Germany Fiducial Markers, by Type USD Million (2025-2030)
  • Table 328. Germany Fiducial Markers, by Application USD Million (2025-2030)
  • Table 329. Germany Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 330. Germany Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 331. France Fiducial Markers, by Type USD Million (2025-2030)
  • Table 332. France Fiducial Markers, by Application USD Million (2025-2030)
  • Table 333. France Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 334. France Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 335. Italy Fiducial Markers, by Type USD Million (2025-2030)
  • Table 336. Italy Fiducial Markers, by Application USD Million (2025-2030)
  • Table 337. Italy Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 338. Italy Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 339. United Kingdom Fiducial Markers, by Type USD Million (2025-2030)
  • Table 340. United Kingdom Fiducial Markers, by Application USD Million (2025-2030)
  • Table 341. United Kingdom Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 342. United Kingdom Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 343. Netherlands Fiducial Markers, by Type USD Million (2025-2030)
  • Table 344. Netherlands Fiducial Markers, by Application USD Million (2025-2030)
  • Table 345. Netherlands Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 346. Netherlands Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 347. Rest of Europe Fiducial Markers, by Type USD Million (2025-2030)
  • Table 348. Rest of Europe Fiducial Markers, by Application USD Million (2025-2030)
  • Table 349. Rest of Europe Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 350. Rest of Europe Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 351. MEA Fiducial Markers, by Country USD Million (2025-2030)
  • Table 352. MEA Fiducial Markers, by Type USD Million (2025-2030)
  • Table 353. MEA Fiducial Markers, by Application USD Million (2025-2030)
  • Table 354. MEA Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 355. MEA Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 356. Middle East Fiducial Markers, by Type USD Million (2025-2030)
  • Table 357. Middle East Fiducial Markers, by Application USD Million (2025-2030)
  • Table 358. Middle East Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 359. Middle East Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 360. Africa Fiducial Markers, by Type USD Million (2025-2030)
  • Table 361. Africa Fiducial Markers, by Application USD Million (2025-2030)
  • Table 362. Africa Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 363. Africa Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 364. North America Fiducial Markers, by Country USD Million (2025-2030)
  • Table 365. North America Fiducial Markers, by Type USD Million (2025-2030)
  • Table 366. North America Fiducial Markers, by Application USD Million (2025-2030)
  • Table 367. North America Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 368. North America Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 369. United States Fiducial Markers, by Type USD Million (2025-2030)
  • Table 370. United States Fiducial Markers, by Application USD Million (2025-2030)
  • Table 371. United States Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 372. United States Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 373. Canada Fiducial Markers, by Type USD Million (2025-2030)
  • Table 374. Canada Fiducial Markers, by Application USD Million (2025-2030)
  • Table 375. Canada Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 376. Canada Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 377. Mexico Fiducial Markers, by Type USD Million (2025-2030)
  • Table 378. Mexico Fiducial Markers, by Application USD Million (2025-2030)
  • Table 379. Mexico Fiducial Markers, by Cancer USD Million (2025-2030)
  • Table 380. Mexico Fiducial Markers, by Modality USD Million (2025-2030)
  • Table 381. Fiducial Markers Sales: by Type(K Unit)
  • Table 382. Fiducial Markers Sales Polymer-Based Markers , by Region K Unit (2025-2030)
  • Table 383. Fiducial Markers Sales Metal-Based Markers , by Region K Unit (2025-2030)
  • Table 384. Fiducial Markers Sales Others , by Region K Unit (2025-2030)
  • Table 385. Fiducial Markers Sales: by Application(K Unit)
  • Table 386. Fiducial Markers Sales Hospitals , by Region K Unit (2025-2030)
  • Table 387. Fiducial Markers Sales Radiotherapy Centers , by Region K Unit (2025-2030)
  • Table 388. Fiducial Markers Sales Cancer Research Institutes , by Region K Unit (2025-2030)
  • Table 389. Fiducial Markers Sales Others , by Region K Unit (2025-2030)
  • Table 390. Fiducial Markers Sales: by Modality(K Unit)
  • Table 391. Fiducial Markers Sales CT/CBCT , by Region K Unit (2025-2030)
  • Table 392. Fiducial Markers Sales MRI , by Region K Unit (2025-2030)
  • Table 393. Fiducial Markers Sales Ultrasound , by Region K Unit (2025-2030)
  • Table 394. Fiducial Markers Sales Radiotherapy , by Region K Unit (2025-2030)
  • Table 395. South America Fiducial Markers Sales, by Country K Unit (2025-2030)
  • Table 396. South America Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 397. South America Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 398. South America Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 399. South America Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 400. Brazil Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 401. Brazil Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 402. Brazil Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 403. Brazil Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 404. Argentina Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 405. Argentina Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 406. Argentina Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 407. Argentina Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 408. Rest of South America Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 409. Rest of South America Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 410. Rest of South America Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 411. Rest of South America Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 412. Asia Pacific Fiducial Markers Sales, by Country K Unit (2025-2030)
  • Table 413. Asia Pacific Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 414. Asia Pacific Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 415. Asia Pacific Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 416. Asia Pacific Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 417. China Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 418. China Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 419. China Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 420. China Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 421. Japan Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 422. Japan Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 423. Japan Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 424. Japan Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 425. India Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 426. India Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 427. India Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 428. India Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 429. South Korea Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 430. South Korea Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 431. South Korea Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 432. South Korea Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 433. Taiwan Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 434. Taiwan Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 435. Taiwan Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 436. Taiwan Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 437. Australia Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 438. Australia Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 439. Australia Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 440. Australia Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 441. Rest of Asia-Pacific Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 442. Rest of Asia-Pacific Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 443. Rest of Asia-Pacific Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 444. Rest of Asia-Pacific Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 445. Europe Fiducial Markers Sales, by Country K Unit (2025-2030)
  • Table 446. Europe Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 447. Europe Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 448. Europe Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 449. Europe Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 450. Germany Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 451. Germany Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 452. Germany Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 453. Germany Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 454. France Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 455. France Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 456. France Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 457. France Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 458. Italy Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 459. Italy Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 460. Italy Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 461. Italy Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 462. United Kingdom Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 463. United Kingdom Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 464. United Kingdom Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 465. United Kingdom Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 466. Netherlands Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 467. Netherlands Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 468. Netherlands Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 469. Netherlands Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 470. Rest of Europe Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 471. Rest of Europe Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 472. Rest of Europe Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 473. Rest of Europe Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 474. MEA Fiducial Markers Sales, by Country K Unit (2025-2030)
  • Table 475. MEA Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 476. MEA Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 477. MEA Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 478. MEA Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 479. Middle East Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 480. Middle East Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 481. Middle East Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 482. Middle East Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 483. Africa Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 484. Africa Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 485. Africa Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 486. Africa Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 487. North America Fiducial Markers Sales, by Country K Unit (2025-2030)
  • Table 488. North America Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 489. North America Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 490. North America Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 491. North America Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 492. United States Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 493. United States Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 494. United States Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 495. United States Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 496. Canada Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 497. Canada Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 498. Canada Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 499. Canada Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 500. Mexico Fiducial Markers Sales, by Type K Unit (2025-2030)
  • Table 501. Mexico Fiducial Markers Sales, by Application K Unit (2025-2030)
  • Table 502. Mexico Fiducial Markers Sales, by Cancer K Unit (2025-2030)
  • Table 503. Mexico Fiducial Markers Sales, by Modality K Unit (2025-2030)
  • Table 504. Fiducial Markers: by Type(USD/Units)
  • Table 505. Research Programs/Design for This Report
  • Table 506. Key Data Information from Secondary Sources
  • Table 507. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Fiducial Markers: by Type USD Million (2018-2023)
  • Figure 5. Global Fiducial Markers: by Application USD Million (2018-2023)
  • Figure 6. Global Fiducial Markers: by Modality USD Million (2018-2023)
  • Figure 7. South America Fiducial Markers Share (%), by Country
  • Figure 8. Asia Pacific Fiducial Markers Share (%), by Country
  • Figure 9. Europe Fiducial Markers Share (%), by Country
  • Figure 10. MEA Fiducial Markers Share (%), by Country
  • Figure 11. North America Fiducial Markers Share (%), by Country
  • Figure 12. Global Fiducial Markers: by Type K Unit (2018-2023)
  • Figure 13. Global Fiducial Markers: by Application K Unit (2018-2023)
  • Figure 14. Global Fiducial Markers: by Modality K Unit (2018-2023)
  • Figure 15. South America Fiducial Markers Share (%), by Country
  • Figure 16. Asia Pacific Fiducial Markers Share (%), by Country
  • Figure 17. Europe Fiducial Markers Share (%), by Country
  • Figure 18. MEA Fiducial Markers Share (%), by Country
  • Figure 19. North America Fiducial Markers Share (%), by Country
  • Figure 20. Global Fiducial Markers: by Type USD/Units (2018-2023)
  • Figure 21. Global Fiducial Markers share by Players 2023 (%)
  • Figure 22. Global Fiducial Markers share by Players (Top 3) 2023(%)
  • Figure 23. Global Fiducial Markers share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. CIVCO Radiotherapy (United States) Revenue, Net Income and Gross profit
  • Figure 26. CIVCO Radiotherapy (United States) Revenue: by Geography 2023
  • Figure 27. IZI Medical Products (United States) Revenue, Net Income and Gross profit
  • Figure 28. IZI Medical Products (United States) Revenue: by Geography 2023
  • Figure 29. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Boston Scientific Corporation (United States) Revenue: by Geography 2023
  • Figure 31. Naslund Medical AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 32. Naslund Medical AB (Sweden) Revenue: by Geography 2023
  • Figure 33. IBA (Belgium) Revenue, Net Income and Gross profit
  • Figure 34. IBA (Belgium) Revenue: by Geography 2023
  • Figure 35. Best Medical International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Best Medical International, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Nanovi A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 38. Nanovi A/S (Denmark) Revenue: by Geography 2023
  • Figure 39. Carbon Medical Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 40. Carbon Medical Technologies (United States) Revenue: by Geography 2023
  • Figure 41. Eckert & Ziegler (Germany) Revenue, Net Income and Gross profit
  • Figure 42. Eckert & Ziegler (Germany) Revenue: by Geography 2023
  • Figure 43. Innovative Oncology Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 44. Innovative Oncology Solutions (United States) Revenue: by Geography 2023
  • Figure 45. Global Fiducial Markers: by Type USD Million (2025-2030)
  • Figure 46. Global Fiducial Markers: by Application USD Million (2025-2030)
  • Figure 47. Global Fiducial Markers: by Modality USD Million (2025-2030)
  • Figure 48. South America Fiducial Markers Share (%), by Country
  • Figure 49. Asia Pacific Fiducial Markers Share (%), by Country
  • Figure 50. Europe Fiducial Markers Share (%), by Country
  • Figure 51. MEA Fiducial Markers Share (%), by Country
  • Figure 52. North America Fiducial Markers Share (%), by Country
  • Figure 53. Global Fiducial Markers: by Type K Unit (2025-2030)
  • Figure 54. Global Fiducial Markers: by Application K Unit (2025-2030)
  • Figure 55. Global Fiducial Markers: by Modality K Unit (2025-2030)
  • Figure 56. South America Fiducial Markers Share (%), by Country
  • Figure 57. Asia Pacific Fiducial Markers Share (%), by Country
  • Figure 58. Europe Fiducial Markers Share (%), by Country
  • Figure 59. MEA Fiducial Markers Share (%), by Country
  • Figure 60. North America Fiducial Markers Share (%), by Country
  • Figure 61. Global Fiducial Markers: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • CIVCO Radiotherapy (United States)
  • IZI Medical Products (United States)
  • Boston Scientific Corporation (United States)
  • Naslund Medical AB (Sweden)
  • IBA (Belgium)
  • Best Medical International, Inc. (United States)
  • Nanovi A/S (Denmark)
  • Carbon Medical Technologies (United States)
  • Eckert & Ziegler (Germany)
  • Innovative Oncology Solutions (United States)
Additional players considered in the study are as follows:
Medtronic (Ireland) , QlRad Inc. (United States) , JJ-Medtech (Netherlands) , QFIX (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 158 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Fiducial Markers Market Quantitative research analysis
Global Fiducial Markers Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as CIVCO Radiotherapy (United States), IZI Medical Products (United States), Boston Scientific Corporation (United States), Naslund Medical AB (Sweden), IBA (Belgium), Best Medical International, Inc. (United States), Nanovi A/S (Denmark), Carbon Medical Technologies (United States), Eckert & Ziegler (Germany) and Innovative Oncology Solutions (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Investments and Funding for Cancer Research" is seen as one of major influencing trends for Fiducial Markers Market during projected period 2023-2030.
The Fiducial Markers market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Fiducial Markers Market Report?

Have a Query? Click Here

Other Related Reports

Inhaler Devices Comprehensive Study by Type (Pressurized Metered Dose Inhaler (pMDI), Dry Powder Inhaler (DPI), Soft Mist Inhaler (SMI)), Application (Residential, Hospital, Clinic, Respiratory Care ...
$ 3800
Pregnancy Kits Comprehensive Study by Type (Digital Devices, Line Indicators, Others), Application (Hospitals, Clinics, Households, Others), Distribution Channel (Online Pharmacies, Hospital Pharmaci...
$ 3450
Extremity Products Comprehensive Study by Type (Upper Extremities, Lower Extremities), Application (Hospitals, Clinics, ASCs) Players and Region - Global Market Outlook to 2025
$ 3500
Disability Devices Comprehensive Study by Type (Vision Aids, Hearing Aids, Mobility Aids {Wheelchairs and Mobility Scooters}), Application (Hospitals, Home Care, Ambulatory Care Centers, Rehabilitati...
$ 3450
Skin Hooks Comprehensive Study by Type (Joseph Skin Hooks, Kleinert-Kutz Hook, Gillies Skin Hook, Others), Application (Abdomen Surgery, Cosmetic Surgery, Vascular Surgery, Others), Sales Channel (Di...
$ 3350
Disposable Inflation Devices Comprehensive Study by Type (Capacity 20ml, Capacity 30ml, Capacity 60ml, Others), Application (Angioplasty and Cardiac Procedures, Endoscopy and Gastrointestinal Procedu...
$ 3500